ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.283,62
0,00%
S&P 500
5.297,10
0,00%
US Dollar vs BRL
5,1344
0,08%
Bitcoin
66.348,26
1,70%
Brent Oil
83,215
0,01%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Eagle Pharmaceuticals Inc (EGRX)

  7. Eagle Pharmaceuticals Inc (EGRX) Notícias

EGRX

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EGRX
DataHoraFonteTítuloCódigoCompanhia
15/05/202410:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EGRXEagle Pharmaceuticals Inc
10/05/202418:27Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:EGRXEagle Pharmaceuticals Inc
01/03/202418:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EGRXEagle Pharmaceuticals Inc
14/02/202419:09Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EGRXEagle Pharmaceuticals Inc
13/02/202417:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EGRXEagle Pharmaceuticals Inc
12/02/202415:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EGRXEagle Pharmaceuticals Inc
09/02/202407:45PR Newswire (US)Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRXNASDAQ:EGRXEagle Pharmaceuticals Inc
02/02/202407:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)NASDAQ:EGRXEagle Pharmaceuticals Inc
18/01/202408:50GlobeNewswire Inc.Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property PortfolioNASDAQ:EGRXEagle Pharmaceuticals Inc
22/12/202319:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:EGRXEagle Pharmaceuticals Inc
06/12/202318:05GlobeNewswire Inc.Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York CityNASDAQ:EGRXEagle Pharmaceuticals Inc
09/11/202309:30GlobeNewswire Inc.Eagle Delays Third Quarter 2023 Results and Conference CallNASDAQ:EGRXEagle Pharmaceuticals Inc
08/11/202310:30GlobeNewswire Inc.Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023NASDAQ:EGRXEagle Pharmaceuticals Inc
02/11/202317:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EGRXEagle Pharmaceuticals Inc
24/10/202309:40GlobeNewswire Inc.Eagle Pharmaceuticals Granted Patent for PEMFEXY®NASDAQ:EGRXEagle Pharmaceuticals Inc
23/10/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMSNASDAQ:EGRXEagle Pharmaceuticals Inc
04/10/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual MeetingNASDAQ:EGRXEagle Pharmaceuticals Inc
19/09/202317:05GlobeNewswire Inc.Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023NASDAQ:EGRXEagle Pharmaceuticals Inc
11/09/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial ResistanceNASDAQ:EGRXEagle Pharmaceuticals Inc
30/08/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) ConferenceNASDAQ:EGRXEagle Pharmaceuticals Inc
29/08/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal WomenNASDAQ:EGRXEagle Pharmaceuticals Inc
22/08/202317:05GlobeNewswire Inc.Eagle Pharmaceuticals to Present at Two Upcoming Healthcare ConferencesNASDAQ:EGRXEagle Pharmaceuticals Inc
17/08/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ GuidanceNASDAQ:EGRXEagle Pharmaceuticals Inc
09/08/202317:17Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:EGRXEagle Pharmaceuticals Inc
08/08/202317:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EGRXEagle Pharmaceuticals Inc
08/08/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals Reports Second Quarter 2023 ResultsNASDAQ:EGRXEagle Pharmaceuticals Inc
01/08/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023NASDAQ:EGRXEagle Pharmaceuticals Inc
31/07/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ GuidanceNASDAQ:EGRXEagle Pharmaceuticals Inc
24/07/202307:50GlobeNewswire Inc.Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)NASDAQ:EGRXEagle Pharmaceuticals Inc
15/06/202308:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EGRXEagle Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EGRX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HBOR3
HELBOR ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
BRSR6
BANRISUL PNB
BOV
TPIS3
TRIUNFO PART ON
BOV
GFSA3
GAFISA ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
COGN3
COGNA ON
BOV
IRBR3
IRB BRASIL ON
BOV
LIGT3
LIGHT ON
BOV
BPAN4
BANCO PAN PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados